Literature DB >> 17704356

Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat.

Eduardo Candelario-Jalil1, Saeid Taheri, Yi Yang, Rohit Sood, Mark Grossetete, Eduardo Y Estrada, Bernd L Fiebich, Gary A Rosenberg.   

Abstract

Increased permeability of the blood-brain barrier (BBB) is important in neurological disorders. Neuroinflammation is associated with increased BBB breakdown and brain injury. Tumor necrosis factor (TNF)-alpha is involved in BBB injury and edema formation through a mechanism involving matrix metalloproteinase (MMP) up-regulation. There is emerging evidence indicating that cyclooxygenase (COX) inhibition limits BBB disruption following ischemic stroke and bacterial meningitis, but the mechanisms involved are not known. We used intracerebral injection of TNF-alpha to study the effect of COX inhibition on TNF-alpha-induced BBB breakdown, MMP expression/activity, and oxidative stress. BBB disruption was evaluated by the uptake of (14)C-sucrose into the brain and by magnetic resonance imaging utilizing gadolinium-diethylenetriaminepentaacetic acid as a paramagnetic contrast agent. Using selective inhibitors of each COX isoform, we found that COX-1 activity is more important than COX-2 in BBB opening. TNF-alpha induced a significant up-regulation of gelatinase B (MMP-9), stromelysin-1 (MMP-3), and COX-2. In addition, TNF-alpha significantly depleted glutathione as compared with saline. Indomethacin (10 mg/kg i.p.), an inhibitor of COX-1 and COX-2, reduced BBB damage at 24 h. Indomethacin significantly attenuated MMP-9 and MMP-3 expression and activation and prevented the loss of endogenous radical scavenging capacity following intracerebral injection of TNF-alpha. Our results show for the first time that BBB disruption during neuroinflammation can be significantly reduced by administration of COX inhibitors. Modulation of COX in brain injury by COX inhibitors or agents modulating prostaglandin E(2) formation/signaling may be useful in clinical settings associated with BBB disruption.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17704356     DOI: 10.1124/jpet.107.127035

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  63 in total

Review 1.  Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.

Authors:  Saba Aïd; Francesca Bosetti
Journal:  Biochimie       Date:  2010-09-22       Impact factor: 4.079

Review 2.  Factors controlling permeability of the blood-brain barrier.

Authors:  Mohammed M A Almutairi; Chen Gong; Yuexian G Xu; Yanzhong Chang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

Review 3.  From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.

Authors:  William A Banks
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

4.  Anti-Inflammatory Agents for Cancer Therapy.

Authors:  Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Journal:  Mol Cell Pharmacol       Date:  2009

5.  Vasopressin Impairment During Sepsis Is Associated with Hypothalamic Intrinsic Apoptotic Pathway and Microglial Activation.

Authors:  Luis Henrique Angenendt da Costa; Nilton Nascimento Dos Santos Júnior; Carlos Henrique Rocha Catalão; Tarek Sharshar; Fabrice Chrétien; Maria José Alves da Rocha
Journal:  Mol Neurobiol       Date:  2016-09-08       Impact factor: 5.590

6.  Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas.

Authors:  Astrid Weyerbrock; Stuart Walbridge; Joseph E Saavedra; Larry K Keefer; Edward H Oldfield
Journal:  Neuro Oncol       Date:  2010-11-01       Impact factor: 12.300

7.  Endothelial-specific Crif1 deletion induces BBB maturation and disruption via the alteration of actin dynamics by impaired mitochondrial respiration.

Authors:  Min Joung Lee; Yunseon Jang; Jeongsu Han; Soo J Kim; Xianshu Ju; Yu Lim Lee; Jianchen Cui; Jiebo Zhu; Min Jeong Ryu; Song-Yi Choi; Woosuk Chung; Chaejeong Heo; Hyon-Seung Yi; Hyun Jin Kim; Yang H Huh; Sookja K Chung; Minho Shong; Gi-Ryang Kweon; Jun Young Heo
Journal:  J Cereb Blood Flow Metab       Date:  2020-01-27       Impact factor: 6.200

8.  Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced blood-brain barrier disruption through matrix metalloproteinase activity.

Authors:  Saba Aid; Afonso C Silva; Eduardo Candelario-Jalil; Sang-Ho Choi; Gary A Rosenberg; Francesca Bosetti
Journal:  J Cereb Blood Flow Metab       Date:  2009-10-21       Impact factor: 6.200

Review 9.  Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition.

Authors:  May Hamza; Raymond A Dionne
Journal:  Curr Mol Pharmacol       Date:  2009-01       Impact factor: 3.339

10.  Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury.

Authors:  Mark Grossetete; Jeremy Phelps; Leopold Arko; Howard Yonas; Gary A Rosenberg
Journal:  Neurosurgery       Date:  2009-10       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.